Publikationen, an denen er mitarbeitet RAFAEL RODRÍGUEZ PUERTAS (71)

2024

  1. Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers

    Vaccine, Vol. 42, Núm. 18, pp. 3916-3929

  2. Frontal Cortex Lipid Alterations During the Onset of Alzheimer’s Disease

    Journal of Alzheimer's Disease, Vol. 98, Núm. 4, pp. 1515-1532

  3. Neurolipid systems: A new target for the treatment of dementia

    Basic and Clinical Pharmacology and Toxicology, Vol. 135, Núm. 3, pp. 225-236

  4. Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

    Neurobiology of Disease, Vol. 202

2023

  1. Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system

    Cannabis Use, Neurobiology, Psychology, and Treatment (Elsevier), pp. 417-430

  2. Mass Spectrometry for the Advancement of Lipid Analysis in Alzheimer’s Research

    Methods in Molecular Biology (Humana Press Inc.), pp. 245-259

  3. Microarrays, Enzymatic Assays, and MALDI-MS for Determining Specific Alterations to Mitochondrial Electron Transport Chain Activity, ROS Formation, and Lipid Composition in a Monkey Model of Parkinson’s Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 6

  4. Neuroanatomical characterization of the G protein-coupled receptor activity evoked by galanin-related ligands

    Journal of Chemical Neuroanatomy, Vol. 128

2022

  1. Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion

    ACS Pharmacology and Translational Science, Vol. 5, Núm. 9, pp. 791-802

  2. Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

    eLife, Vol. 11

  3. Handling and novel object recognition modulate fear response and endocannabinoid signaling in nucleus basalis magnocellularis

    European Journal of Neuroscience, Vol. 55, Núm. 6, pp. 1532-1546

2021

  1. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 108

  2. Modulation of neurolipid signaling and specific lipid species in the triple transgenic mouse model of alzheimer’s disease

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  3. Pharmacological ablation of astrocytes reduces Aβ degradation and synaptic connectivity in an ex vivo model of Alzheimer’s disease

    Journal of Neuroinflammation, Vol. 18, Núm. 1

  4. Specific Phospholipid Modulation by Muscarinic Signaling in a Rat Lesion Model of Alzheimer's Disease

    ACS Chemical Neuroscience, Vol. 12, Núm. 12, pp. 2167-2181

2020

  1. ACE2 activators for the treatment of COVID 19 patients

    Journal of Medical Virology

  2. Lisofosfolipidoen eta Alzheimer gaixotasunaren arteko erlazioa: etorkizuneko itu farmakologikoaren bila.

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 38, pp. 55-71

  3. Neuropeptides and neurolipids: What they are and how they relate to Alzheimer’s disease

    Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2 (Elsevier), pp. 423-439

  4. Neurotransmitter receptors in Alzheimer’s disease: From glutamatergic to cholinergic receptors

    Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2 (Elsevier), pp. 441-456

  5. Spinal Inhibition of GABAB Receptors by the Extracellular Matrix Protein Fibulin-2 in Neuropathic Rats

    Frontiers in Cellular Neuroscience, Vol. 14